BR112020003025A2 - métodos de tratamento de osteoartrite com gel transdérmico de canabidiol - Google Patents

métodos de tratamento de osteoartrite com gel transdérmico de canabidiol Download PDF

Info

Publication number
BR112020003025A2
BR112020003025A2 BR112020003025-2A BR112020003025A BR112020003025A2 BR 112020003025 A2 BR112020003025 A2 BR 112020003025A2 BR 112020003025 A BR112020003025 A BR 112020003025A BR 112020003025 A2 BR112020003025 A2 BR 112020003025A2
Authority
BR
Brazil
Prior art keywords
cbd
fact
cannabidiol
pain
patients
Prior art date
Application number
BR112020003025-2A
Other languages
English (en)
Portuguese (pt)
Inventor
John Messenheimer
Nancy Tich
Donna Gutterman
Daniel Clauw
Original Assignee
Zynerba Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals, Inc. filed Critical Zynerba Pharmaceuticals, Inc.
Publication of BR112020003025A2 publication Critical patent/BR112020003025A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR112020003025-2A 2017-08-14 2018-08-13 métodos de tratamento de osteoartrite com gel transdérmico de canabidiol BR112020003025A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762545468P 2017-08-14 2017-08-14
US62/545,468 2017-08-14
US201862661733P 2018-04-24 2018-04-24
US62/661,733 2018-04-24
PCT/IB2018/056090 WO2019034985A1 (en) 2017-08-14 2018-08-13 METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL

Publications (1)

Publication Number Publication Date
BR112020003025A2 true BR112020003025A2 (pt) 2020-08-04

Family

ID=65362584

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020003025-2A BR112020003025A2 (pt) 2017-08-14 2018-08-13 métodos de tratamento de osteoartrite com gel transdérmico de canabidiol

Country Status (11)

Country Link
US (4) US20200170963A1 (cg-RX-API-DMAC7.html)
EP (1) EP3668500A4 (cg-RX-API-DMAC7.html)
JP (3) JP2020530857A (cg-RX-API-DMAC7.html)
KR (1) KR20200054171A (cg-RX-API-DMAC7.html)
AU (2) AU2018318425A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020003025A2 (cg-RX-API-DMAC7.html)
CA (1) CA3072849A1 (cg-RX-API-DMAC7.html)
IL (2) IL301622A (cg-RX-API-DMAC7.html)
JO (1) JOP20200031A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020001768A (cg-RX-API-DMAC7.html)
WO (1) WO2019034985A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
IL325123A (en) 2018-12-14 2026-02-01 Harmony Biosciences Man Inc Treating 22q11.2 Deficiency Syndrome with Cannabidiol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
EP4725549A3 (en) * 2019-10-13 2026-06-10 FibroBiologics, Inc. Cannabidiol adjuvant therapy for treatment of disc degenerative disease
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス,インコーポレイテッド カンナビジオールの経皮送達
TWI902836B (zh) * 2020-06-29 2025-11-01 美商和諧生物科學管理股份有限公司 以大麻二酚(cannabidiol)治療X染色體脆折症候群
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
EP4098254A1 (en) * 2021-06-04 2022-12-07 Assistance Publique, Hopitaux De Paris Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
JP2025535174A (ja) * 2022-10-17 2025-10-22 インベンテージ ラボ インコーポレイテッド 炎症性疾患の治療または予防のための徐放型注射用組成物およびその製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
ES2396976T3 (es) * 2005-05-25 2013-03-01 Calosyn Pharma, Inc Método y composición para tratar osteoartritis
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
DK2376121T4 (da) * 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
WO2010127033A1 (en) * 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
EP2864477A4 (en) * 2012-06-26 2016-02-17 Amberdale Entpr Pty Ltd ISOLATION OF STEM CELLS FROM ADIPOSE TISSUE BY ULTRASONIC CAVITATION, AND METHODS OF USE
WO2016011451A1 (en) * 2014-07-18 2016-01-21 Medipath, Inc. Compositions and methods for physiological delivery using cannabidiol
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法

Also Published As

Publication number Publication date
US20200170963A1 (en) 2020-06-04
KR20200054171A (ko) 2020-05-19
JP2023109969A (ja) 2023-08-08
CA3072849A1 (en) 2019-02-21
MX2020001768A (es) 2020-12-03
EP3668500A4 (en) 2021-04-28
WO2019034985A1 (en) 2019-02-21
JP7590803B2 (ja) 2024-11-27
JP2020530857A (ja) 2020-10-29
EP3668500A1 (en) 2020-06-24
AU2018318425A1 (en) 2020-02-27
JP2025024068A (ja) 2025-02-19
US20250268843A1 (en) 2025-08-28
US20240148669A1 (en) 2024-05-09
IL301622A (en) 2023-05-01
IL272593A (en) 2020-03-31
US20240189255A1 (en) 2024-06-13
JOP20200031A1 (ar) 2020-02-12
AU2024205778A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
US20240148669A1 (en) Methods of treatment of osteoarthritis with transdermal cannabidiol gel
CN101198362B (zh) 在癌症化疗和放疗时保护细胞的局部血管收缩剂制品和方法
JP6673924B2 (ja) 肝機能障害および/または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
BR112020004947A2 (pt) canabidiol transdérmico sintético para o tratamento de epilepsia focal em adultos
Scheinfeld Topical treatments of skin pain: a general review with a focus on hidradenitis suppurativa with topical agents
WO2016044131A1 (en) Method of treating prader-willi syndrome
JP2022519721A (ja) 睡眠時無呼吸を治療するための方法および組成物
Aydın et al. Pain prevention with intraoperative ketamine in outpatient children undergoing tonsillectomy or tonsillectomy and adenotomy
JP2022546456A (ja) 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
RU2616520C2 (ru) Лечение симптомов, связанных с гастропарезом у женщин
Joppich et al. Analgesic efficacy and tolerability of intravenous morphine versus combined intravenous morphine and oxycodone in a 2-center, randomized, double-blind, pilot trial of patients with moderate to severe pain after total hip replacement
ES2447829T3 (es) Combinación para el tratamiento de la osteoartritis
TW202440106A (zh) 用於治療勃起障礙之化合物
Tankl et al. To evaluate role of gabapentin as a preemptive analgesic in the patients undergoing modified radical mastectomy
Joseph et al. Efinaconazole 10% solution in the treatment of onychomycosis of the toenails
EP4132497A1 (en) Endoxifen for the treatment of bipolar i disorder
Fang et al. Phase 1 single-centre, placebo and levobupivacaine controlled study in healthy volunteers to assess the safety, tolerability, efficacy, and pharmacokinetics of LL10, a novel long-acting local anaesthetic
JP5376481B1 (ja) 経皮吸収用医薬組成物
IL230174A (en) Pharmaceutical composition for the treatment of premature ejaculation
Khokar et al. Oral versus intravenous paracetamol for perioperative analgesia in patients undergoing total abdominal hysterectomy-A randomised double-blind controlled trial
Kolling et al. The use of extemporaneously compounded 1% tetracaine to improve adherence with clotrimazole 1% topical solution in the treatment of ear infection: a case report
Sigg et al. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium-and long-term efficacy and safety of topical rapamycin
Soroka et al. Ketamine in affective disorders–expectations and limitations
Ongzalima et al. The Foot and Ankle Online Journal
JPWO2019135363A1 (ja) 腱滑膜病変を主体とした疾患の治療薬

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HARMONY BIOSCIENCES MANAGEMENT, INC. (US)

B25G Requested change of headquarter approved

Owner name: HARMONY BIOSCIENCES MANAGEMENT, INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]